SCHEMBL169939

SCHEMBL169939

CCCCCCC(CCCCCC)(CCCCCC)C(=O)OCC

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.61
CYP4A11 Q02928 2/20 0.61
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
MAPT P10636 1/20 0.59
ATM Q13315 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
HTT P42858 1/20 0.50
THRB P10828 1/20 0.47
PKM P14618 1/20 0.47
CES2 O00748 1/20 0.42
NAAA Q02083 1/20 0.41
DGKA P23743 1/20 0.41
GGPS1 O95749 1/20 0.41
SMPD1 P17405 1/20 0.40
FAAH O00519 2/20 0.40
FDPS P14324 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718008 1.00 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL717168 1.00 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL87652 1.00 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL28984795 1.00 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL10871818 1.00 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL28462437 0.98 CYP4F2 (0.59) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL503887 0.94 CYP4F2 (0.56) CYP4F2CYP4A11MEN1KMT2AMAPT
Acetic Acid SCHEMBL8601641 0.94 MEN1 (0.58) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL6531912 0.94 CYP4F2 (0.56) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL369993 0.94 CYP4F2 (0.56) CYP4F2CYP4A11MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 920 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113660932-B Phenyl derivatives having pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same 景凯生物科技股份有限公司 2024-07-12 CN disclosed
CN-118265453-A Protein aggregation inhibiting compounds for plant disease control 马克斯·普朗克科学促进学会 2024-06-28 CN disclosed
CN-115515956-B Benzimidazole derivative, and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-06-25 CN disclosed
CN-115461334-B Benzimidazole derivative, and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-06-21 CN disclosed
EP-4384013-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) 2024-06-19 EP disclosed
CN-112437773-B Catechol derivatives or salts thereof, process for preparing the same and pharmaceutical compositions containing the same 六合医药科技有限公司 2024-06-11 CN disclosed
CN-118126046-A Substituted macrocyclic compound, and preparation method and application thereof 深圳信立泰药业股份有限公司 2024-06-04 CN disclosed
US-20240166627-A1 Terpyridinedione compound or salt thereof, and preparation method and application thereof SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2024-05-23 US disclosed
CN-115515938-B Salts of FXIa inhibitor compounds, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-05-10 CN disclosed
CN-117919443-A Covalent organic framework combining diagnosis of hypoxia-activated therapy and self-accelerating drug release to coordinate cancer immunotherapy 长春工业大学 2024-04-26 CN disclosed
EP-0443513-A2 Azoxy compounds KOWA COMPANY, LTD. (JP) 1991-08-28 EP disclosed
US-4990531-A Antispasmodic agents ROUSSEL UCLAF (FR) 1991-02-05 US disclosed
EP-0382884-A1 Oxazolidinedione compounds, the process for preparing the same and herbicidal composition containing the same SAGAMI CHEMICAL RESEARCH CENTER (JP) 1990-08-22 EP disclosed
US-4948804-A TREATING PSYCHOLOGICAL DISORDERS ROUSSEL UCLAF (FR) 1990-08-14 US disclosed
EP-0347902-A2 Pyrrolecarboxylic acid derivatives Mitsubishi Chemical Corporation (JP) 1989-12-27 EP disclosed
EP-0346465-A1 1-CARBOXY-1-VYNILOXYIMINOAMINOTHIAZOLE CEPHALOSPORING DERIVATIVES AND PROCESS FOR THEIR PREPARATION BANYU PHARMACEUTICAL CO., LTD. (JP) 1989-12-20 EP disclosed
US-4886903-A Process for production of prostaglandins D2 TEIJIN LIMITED (JP) 1989-12-12 US disclosed
US-4705554-A Benzofuranyloxyphenylurea derivative and herbicidal composition containing it as an active ingredient MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1987-11-10 US disclosed
EP-0224816-A1 Benzofuranyloxyphenylurea derivative and herbicidal composition containing it as an active ingredient MITSUBISHI KASEI CORPORATION (JP) 1987-06-10 EP disclosed
EP-0157637-A2 Heterocyclic compounds THE WELLCOME FOUNDATION LIMITED (GB) 1985-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166627-A1 Terpyridinedione compound or salt thereof, and preparation method and application thereof TNF, MAPKAPK2, MAPK1 CYP4F2 536/4885CYP4A11 378/4885MEN1 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.